Please login to the form below

Not currently logged in

Novartis tops leaderboard at PM Society Digital Media Awards

Secures four wins for two separate campaigns

Novartis Ruder Finn meningitis campaign 

Novartis Vaccines and Diagnostics picked up the largest haul at last week's PM Society Digital Media Awards in London.  

The company's four wins from two campaigns saw it just edge out AstraZeneca, which picked up three prizes, at the annual marketing event.  

Novartis' winning work was led by the Ruder Finn produced Meningitis: Keep Watching campaign (pictured above).  

This picked up awards for best integrated multi-channel campaign and digital patient communications programme - patient education, as well as the social media prize.  

Meanwhile, the pharma company's in-pharmacy vaccination programme by Radical Departures picked up the joint working/NHS partnerships award.  

Close behind Ruder Finn was Digitas Health, which picked up two awards, taking home the craft award – mobile for its Symbicort Mobile App on behalf of AstraZeneca.  

The agency also scored in the craft award – gamification with its JAK Pathways Augmented Reality Challenge for Pfizer.  

The Digital Awards' individual categories were led by GlaxoSmithKline's global digital director Kai Gait, who walked away with the digital pioneer award.  

Meanwhile, the digital project/account management award was picked up by Aurora Healthcare Communication's senior account manager Gill Dunn, while Kristen Grant of Waggener Edstrom was recognised with a high commendation.  

Now in its fifth year, the Digital Media Awards judges reported more consistently high standards across all categories and increased integration of digital into marketing strategies.

30th September 2013

From: Marketing



COVID-19 Updates and Daily News

Featured jobs


Add my company

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

Harness the power of data to map new patient pathways
Oli Hudson, of Wilmington Healthcare, explains why pharma needs to put data at the heart of its bid to support the NHS Reset...
What NORD’s RareInsights® 30-year comparative analysis means to us and our clients at OPEN Health
Peter Jackson
Rethinking our approach to infectious disease preparedness
The importance of long-term strategic investment to prepare for the next threat that emerges...